In silico study of the binding of daunomycin and phenylalanine transfer RNA: probe molecular recognition for structure-based drug design

被引:3
|
作者
Wu, Gonghao [1 ,2 ,3 ]
Li, Jipeng [4 ]
Yang, Jianxin [1 ,2 ,3 ]
Xiao, Xingqing [1 ]
机构
[1] Hainan Univ, Sch Sci, Dept Chem, Haikou 570228, Hainan, Peoples R China
[2] Hainan Univ, Hainan Prov Fine Chem Engn Res Ctr, Haikou 570228, Hainan, Peoples R China
[3] Hainan Univ, Key Lab Green Catalysis & React Engn Haikou, Haikou 570228, Hainan, Peoples R China
[4] Hainan Univ, Sch Mat Sci & Engn, Haikou 570228, Hainan, Peoples R China
基金
海南省自然科学基金; 中国国家自然科学基金;
关键词
BETA-D-GLUCOSIDE; FORCE-FIELD; FREE-ENERGY; CRYSTAL-STRUCTURE; DNA; DOCKING; PEPTIDE; TRNA(LYS3); SIMULATION; RESOLUTION;
D O I
10.1039/d2me00236a
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Rational designs of pharmaceutical compounds targeting specific RNAs require a comprehensive understanding of molecular recognition mechanisms. Knowledge of binding affinity and specificity can be gained via computational modeling and simulation techniques. In this work, an integrated computational strategy combining QM calculation, molecular docking, conventional and adaptive steered MD simulations, and the var-MM/GBSA approach was proposed to probe the binding behaviors of daunomycin (DAU) and phenylalanine transfer RNA (tRNA(Phe)) at a micro-scale level. Gathering experimental information enables us to eliminate improper predictions for the binding of DAU and tRNA(Phe), and the calculations of PMF and Delta G(binding) lead to the identification of the binding structure of the complex. Further, structural and energetic analysis of the DAU:tRNA(Phe) complex revealed that daunomycinone of DAU contributes the intermolecular VDW energies to nucleotides G(15), C-48 and U-59 on tRNA(Phe), responsible for the binding specificity; meanwhile daunosamine contributes the intermolecular ELE + EGB energies to U-50, responsible for the binding affinity.
引用
收藏
页码:786 / 798
页数:13
相关论文
共 50 条
  • [1] Molecular recognition studies to advance structure-based drug design
    Diederich, Francois
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [2] In silico structure-based drug design for GPCRs
    Hirokawa, Takatsugu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 37P - 37P
  • [3] Molecular recognition and structure-based design
    Diederich, Francois N.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [4] Probe the Binding Mode of Aristololactam-β-D-glucoside to Phenylalanine Transfer RNA in Silico
    Xiao, Xingqing
    Zhao, Binwu
    Yang, Li
    Liang, Xiaodong
    Ren, Yingqian
    CHEMISTRYSELECT, 2016, 1 (17): : 5430 - 5439
  • [5] Molecular binding in structure-based drug design: A case study of the population-based annealing genetic algorithms
    Chen, CC
    Wang, LH
    Kao, CY
    Ouhyoung, M
    Chen, WC
    TENTH IEEE INTERNATIONAL CONFERENCE ON TOOLS WITH ARTIFICIAL INTELLIGENCE, PROCEEDINGS, 1998, : 328 - 335
  • [6] Prediction of binding affinities for structure-based drug design
    Brown, S
    Muchmore, SW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U1281 - U1281
  • [7] Molecular Docking and Structure-Based Drug Design Strategies
    Ferreira, Leonardo G.
    dos Santos, Ricardo N.
    Oliva, Glaucius
    Andricopulo, Adriano D.
    MOLECULES, 2015, 20 (07) : 13384 - 13421
  • [8] Structure-based design of an RNA-binding zinc finger
    McColl, DJ
    Honchell, CD
    Frankel, AD
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (17) : 9521 - 9526
  • [9] Structure-based drug design employing solvated molecular footprints
    Guo, Jiaye
    Rizzo, Robert C.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [10] Structure-based drug design: Combinatorial chemistry and molecular modeling
    Kirkpatrick, DL
    Watson, S
    Ulhaq, S
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 1999, 2 (04) : 211 - 221